AYTU BIOPHARMA, INC. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$15M↓-6.5%$-11M↓-1443.1%-13.0%
2025-09-30$14M↓-16.2%$2M↑+33.3%-10.8%
2025-06-30$15M↑+601.7%
2025-03-31$18M↑+31.6%$4M↑+238.3%13.1%
2024-12-31$16M↓-13.5%$788K↑+458.2%-10.4%
2024-09-30$17M↓-7.0%$1M↑+118.2%-5.6%
2024-06-30$2M↓-93.0%
2024-03-31$14M↓-38.3%$-3M↑+59.9%-11.4%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$15M
↓-6.5% -$1M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 65 quarters

margin trajectory tells the operating-leverage story
Gross Margin↓-3.0pts
63.5%
Operating Margin↓-2.5pts
-13.0%
Net Margin↓-74.7pts
-69.8%

Go deeper